Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2002-04-25
2004-10-05
Kifle, Bruck (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S375000, C546S271700, C548S218000
Reexamination Certificate
active
06800648
ABSTRACT:
BACKGROUND OF THE INVENTION
The clinical treatment of schizophrenia has long been defined by the dopamine hypothesis of schizophrenia, which holds that schizophrenia is a result of hyperactivity of dopaminergic neurotransmission, particularly in limbic brain structures such as nucleus accumbens (the mesolimbic dopamine system). Indeed, the positive symptoms of schizophrenia (hallucinations, delusions, thought disorder) are successfully treated with neuroleptics, which block dopamine receptors. However, such treatment is accompanied by the production of movement disorders or dyskinesias (extrapyramidal side effects), due to the blockade of nigrostriatal dopamine receptors. In addition, neuroleptics do not treat the negative symptoms of schizophrenia (social withdrawal, anhedonia, poverty of speech) which are related to a relative hypoactivity of neurotransmission in the mesocortical dopamine system and which respond to treatment by dopamine agonists.
Efforts to induce antipsychotic activity with dopamine autoreceptor agonists have been successful (Corsini et al., Adv. Biochem. Psychopharmacol. 16, 645-648, 1977; Tamminga et al., Psychiatry 398-402, 1986). Dopamine autoreceptor agonists produce a functional antagonism of dopaminergic neurotransmission by the reduction of neuronal firing and the inhibition of dopamine synthesis and release. Since dopamine autoreceptor agonists are partial agonists at postsynaptic dopamine receptors, they provide a residual level of stimulation sufficient to prevent the production of dyskinesias. Indeed, partial agonists are capable of functioning as either agonists or antagonists depending on the level of dopaminergic stimulation in a given tissue or brain region, and would therefore be expected to have efficacy versus both positive and negative symptoms of schizophrenia. Thus, novel dopamine partial agonists are of great interest for the treatment of schizophrenia and related disorders.
REFERENCES:
patent: 5318988 (1994-06-01), Schohe-Loop et al.
patent: 5371094 (1994-12-01), Heine et al.
patent: 5756532 (1998-05-01), Stack et al.
patent: 5869490 (1999-02-01), Stack
patent: WO 97/23485 (1997-07-01), None
patent: WO 91/13872 (1991-09-01), None
patent: WO 97/32871 (1997-09-01), None
patent: WO 98/29415 (1998-07-01), None
patent: WO 98/40386 (1998-09-01), None
patent: WO 00/29397 (2000-05-01), None
Stack Gary P.
Tran Megan
Kifle Bruck
Wyeth
LandOfFree
Antipsychotic aminomethyl derivatives of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Antipsychotic aminomethyl derivatives of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antipsychotic aminomethyl derivatives of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3293570